

**Supplementary table S1.** ESRS based AIP scores in haloperidol-treated schizophrenia patients with different *HTR2C* rs3813929 alleles.

Parkinsonism examination instrument	ESRS based AIP scores in different <i>HTR2C</i> rs3813929 allele carriers	
	C	T
ESRS subscale II for parkinsonism	6 (0; 18)	4 (0; 17)
	U=3731.50; p=0.747	
Expressive automatic movements	0 (0; 2)	0 (0; 1)
	U=3761.00; p=0.794	
Bradykinesia	0 (0; 2)	0 (0; 2)
	U=3785.00; p=0.853	
Rigidity	0 (0; 6)	0 (0; 6)
	U=3719.50; p=0.702	
Gait and posture	0 (0; 2)	0 (0; 2)
	U=3809.00; p=0.907	
Tremor / ESRS subscore Hyperkinesia	0 (0; 8)	0 (0; 6)
	U=3737.50; p=0.731	
Postural stability	0 (0; 1)	0 (0; 0)
	U=3680.00; p=0.563	
ESRS subscale VI (CGI-S of parkinsonism)	2 (0; 4)	3 (0; 4)
	U=4019.00; p=0.637	
SRS subscale VIII (Stage of parkinsonism)	2 (0; 3)	2 (0; 3)
	U=3795.50; p=0.882	
ESRS subscore Hypokinesia	0 (0; 12)	0 (0; 9)
	U=3780.00; p=0.846	

Data are expressed as median (Q1; Q3) and compared with Mann-Whitney U test. Since the *HTR2C* gene is located on the X chromosome and study enrolled only male subjects, for the rs3813929 polymorphism only allele carriers could be analyzed.

**Supplementary table S2.** ESRS based AIP scores in haloperidol-treated schizophrenia patients with different *HTR2C* rs518147 alleles.

Parkinsonism examination instrument	ESRS based AIP scores in different <i>HTR2C</i> rs518147 allele carriers	
	C	T
ESRS subscale II for parkinsonism	6 (0; 18) U=3731.50; p=0.747	4 (0; 17)
Expressive automatic movements	0 (0; 2) U=3761.00; p=0.794	0 (0; 1)
Bradykinesia	0 (0; 2) U=3785.00; p=0.853	0 (0; 2)
Rigidity	0 (0; 6) U=3719.50; p=0.702	0 (0; 6)
Gait and posture	0 (0; 2) U=3809.00; p=0.907	0 (0; 2)
Tremor / ESRS subscore Hyperkinesia	0 (0; 8) U=3737.50; p=0.731	0 (0; 6)
Postural stability	0 (0; 1) U=3680.00; p=0.563	0 (0; 0)
ESRS subscale VI (CGI-S of parkinsonism)	2 (0; 4) U=4019.00; p=0.637	3 (0; 4)
SRS subscale VIII (Stage of parkinsonism)	2 (0; 3) U=3795.50; p=0.882	2 (0; 3)
ESRS subscore Hypokinesia	0 (0; 12) U=3780.00; p=0.846	0 (0; 9)

Data are expressed as median (Q1; Q3) and compared with Mann-Whitney U test. Since the *HTR2C* gene is located on the X chromosome and study enrolled only male subjects, for the rs518147 polymorphism only allele carriers could be analyzed.

**Supplementary table S3.** ESRS based AIP scores in haloperidol-treated schizophrenia patients with different *HTR2C* rs3813929-rs518147 haplotypes.

Parkinsonism examination instrument	ESRS based AIP scores in different <i>HTR2C</i> rs3813929-rs518147 haplotype carriers		
	CC	CG	TC
ESRS subscale II for parkinsonism	0 (0; 20)	9 (0; 18) H=1.14; p=0.567	5 (0; 17)
Expressive movements	0 (0; 1)	0 (0; 2) H=0.35; p=0.838	0 (0; 1)
Bradykinesia	0 (0; 1)	0 (0; 2) H=0.97; p=0.617	0 (0; 2)
Rigidity	0 (0; 6)	0 (0; 6) H=0.20; p=0.905	0 (0; 6)
Gait and posture	0 (0; 2)	0 (0; 2) H=0.88; p=0.644	0 (0; 2)
Tremor / ESRS subscore Hyperkinesia	0 (0; 7)	0 (0; 8) H=0.47; p=0.789	0 (0; 6)
Postural stability	0 (0; 0)	0 (0; 1) H=0.56; p=0.755	0 (0; 0)
ESRS subscale VI (CGI-S of parkinsonism)	0 (0; 3)	3 (0; 4) H=4.53; p=0.104	3 (0; 4)
SRS subscale VIII (Stage of parkinsonism)	0 (0; 3)	2 (0; 3) H=2.50; p=0.287	2 (0; 3)
ESRS subscore Hypokinesia	0 (0; 12)	2 (0; 12) H=0.57; p=0.754	3 (0; 9)

Data are expressed as median (Q1; Q3) and compared with Kruskal-Wallis H test.

**Supplementary table S4.** ESRS based AIP scores in haloperidol-treated schizophrenia patients with different *HTR6* rs1805054 genotypes.

Parkinsonism examination instrument	ESRS based AIP scores in different <i>HTR6</i> rs1805054 genotype carriers		
	CC	CT	TT
ESRS subscale II for parkinsonism	1 (0; 15)	12 (0; 21) <i>H=6.06, p=0.048</i>	14 (5; 21)
Expressive automatic movements	0 (0; 2)	0 (0; 2) <i>H=0.41; p=0.816</i>	0 (0; 2)
Bradykinesia	0 (0; 1)	1 (0; 2) <i>H=2.40; p=0.302</i>	1 (0; 3)
Rigidity	0 (0; 2)	2 (0; 8) <i>H=6.90; p=0.032</i>	4 (0; 8)
Gait and posture	0 (0; 1)	0 (0; 2) <i>H=2.85; p=0.241</i>	1 (0; 2)
Tremor / ESRS subscore Hyperkinesia	0 (0; 6)	0 (0; 9) <i>H=8.89; <b>p=0.012</b></i>	8 (1; 10)
Postural stability	0 (0; 0)	0 (0; 1) <i>H=1.77; p=0.413</i>	0 (0; 1)
ESRS subscale VI (CGI-S of parkinsonism)	2 (0; 4)	3 (0; 4) <i>H=2.92; p=0.232</i>	4 (1; 4)
SRS subscale VIII (Stage of parkinsonism)	1 (0; 3)	2 (0; 3) <i>H=3.23; p=0.199</i>	2 (1; 3)
ESRS subscore Hypokinesia	0 (0; 11)	3 (0; 13) <i>H=3.33; p=0.189</i>	7 (0; 14)

Data are expressed as median (Q1; Q3) and compared with Kruskal-Wallis H test. Statistically significant result is shown in bold, while nominally significant results, rejected after the Bonferroni correction, are shown in italics.

**Supplementary table S5.** ESRS based AIP scores in haloperidol-treated schizophrenia patients with different *SLC6A3* 3'UTR VNTR genotypes.

Parkinsonism examination instrument	ESRS based AIP scores in different <i>SLC6A3</i> 3'UTR VNTR genotype carriers		
	10R/10R	9R/10R	9R/9R
ESRS subscale II for parkinsonism	2 (0; 15)	9 (0; 20) H=3.87; p=0.145	1 (0; 20)
Expressive automatic movements	0 (0; 1)	0 (0; 2) H=0.43; p=0.805	0 (0; 2)
Bradykinesia	0 (0; 1)	0 (0; 2) H=0.31; p=0.856	0 (0; 1)
Rigidity	0 (0; 6)	0 (0; 8) H=1.53; p=0.465	0 (0; 4)
Gait and posture	0 (0; 1)	0 (0; 2) H=0.78; p=0.679	0 (0; 2)
Tremor / ESRS subscore Hyperkinesia	0 (0; 6)	0 (0; 8) H=3.28; p=0.194	0 (0; 8)
Postural stability	0 (0; 0)	0 (0; 1) H=0.61; P=0.737	0 (0; 1)
ESRS subscale VI (CGI-S of parkinsonism)	1 (0; 4)	3 (0; 4) H=5.96; p=0.051	3 (0; 4)
SRS subscale VIII (Stage of parkinsonism)	1 (0; 3)	2 (0; 3) H=5.77; p=0.056	2 (0; 3)
ESRS subscore Hypokinesia	0 (0; 11)	0 (0; 13) H=1.09; p=0.580	0 (0; 10)

Data are expressed as median (Q1; Q3) and compared with Kruskal-Wallis H test. 10R/10R=10 repeats homozygotes; 9R/10R=heterozygotes; 9R/9R=9 repeats homozygotes.